Idorsia issues invitation to 2019 Annual General Meeting of Shareholders

Idorsia Pharmaceuticals Ltd. / Idorsia issues invitation to 2019 Annual General Meeting of Shareholders . Processed and transmitted by West Corporation. The issuer is solely responsible for the content of this announcement.

Allschwil, Switzerland - March 29, 2019
Idorsia Ltd (SIX: IDIA) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting to approve the Business Report of the year ending December 31, 2018 will be held on Friday May 3, 2019 at 11.00 CEST at the Congress Center, Messe Basel, Switzerland.

Notes to Shareholders
The invitation will be published in the Swiss Official Gazette of Commerce (Schweizerisches Handelsamtsblatt) and distributed to Shareholders by post on April 10, 2019, and is available, together with the Company's Annual Report and Compensation Report, on www.idorsia.com/agm.

In order to attend and vote at the Annual General Meeting, shareholders must be registered in the company's shareholder register by April 24, 2019 at the latest.

Notes to the editor

Letter from the Chairman

Dear Shareholders,

It is with great pleasure that I invite you to Idorsia's Annual General Meeting 2019 where we will review the progress made by your company in 2018.

In 2018, Idorsia saw advances on all fronts:

• We advanced our pipeline, bringing four products into Phase 3 development.
• We completed demerger activities, with all core systems now running independently of Actelion.
• We appointed a leader to build our commercial organization, thus taking another step forward towards financial sustainability.
• We strengthened our cash position so as to be able to run our Phase 3 clinical trials and then take strategic decisions on how best to commercialize our assets.

At the upcoming Annual General Meeting, you will have the opportunity to hear more about these achievements and put them into the context of our strategic priorities for building Idorsia into a one of Europe's leading biopharmaceutical companies. You can also find a description of our activities in our Annual Report 2018 at: www.idorsia.com/annual-report.